These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34155899)

  • 21. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible clinical indications of ceftobiprole.
    Barberán J
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):29-33. PubMed ID: 31364339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
    Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
    Gentile I; Buonomo AR; Corcione S; Paradiso L; Giacobbe DR; Bavaro DF; Tiseo G; Sordella F; Bartoletti M; Palmiero G; Vozza A; Vena A; Canta F; Moriello NS; Congera P; Karruli A; Tascini C; Viale P; Bono VD; Falcone M; Carbonara S; Mikulska MK; Bassetti M; Durante-Mangoni E; De Rosa FG; Maraolo AE
    Int J Antimicrob Agents; 2023 Jul; 62(1):106817. PubMed ID: 37061102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
    Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: A systematic review and meta-analysis.
    Jame W; Basgut B; Abdi A
    Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116263. PubMed ID: 38615599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demographics and microbiological profile of pneumonia in United Arab Emirates.
    Al-Muhairi S; Zoubeidi T; Ellis M; Nicholls MG; Safa W; Joseph J
    Monaldi Arch Chest Dis; 2006 Mar; 65(1):13-8. PubMed ID: 16700188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for nosocomial pneumonia.
    Liapikou A; Torres A
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):331-41. PubMed ID: 27347712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.